Abstract
Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.
| Original language | English |
|---|---|
| Pages (from-to) | 251-257 |
| Number of pages | 7 |
| Journal | Cardiovascular Drugs and Therapy |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2002 |
Fingerprint
Keywords
- HMG-CoA reductase inhibitors
- NK-140
- Novel statins
- Pitavastatin
- Pleiotropic effects
- Rosuvastatin
- ZD 4522
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
- Pharmacology
Cite this
Novel statins : Pharmacological and clinical results. / Bolego, Chiara; Poli, Andrea; Cignarella, Andrea; Catapano, Alberico L.; Paoletti, Rodolfo.
In: Cardiovascular Drugs and Therapy, Vol. 16, No. 3, 2002, p. 251-257.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel statins
T2 - Pharmacological and clinical results
AU - Bolego, Chiara
AU - Poli, Andrea
AU - Cignarella, Andrea
AU - Catapano, Alberico L.
AU - Paoletti, Rodolfo
PY - 2002
Y1 - 2002
N2 - Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.
AB - Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.
KW - HMG-CoA reductase inhibitors
KW - NK-140
KW - Novel statins
KW - Pitavastatin
KW - Pleiotropic effects
KW - Rosuvastatin
KW - ZD 4522
UR - http://www.scopus.com/inward/record.url?scp=0036437730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036437730&partnerID=8YFLogxK
U2 - 10.1023/A:1020656607497
DO - 10.1023/A:1020656607497
M3 - Article
C2 - 12374904
AN - SCOPUS:0036437730
VL - 16
SP - 251
EP - 257
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
SN - 0920-3206
IS - 3
ER -